MCUR.CN

Mind Cure Health Inc.

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform VANCOUVER, BC, Sept. 23, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licen... Read More...

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, Sept. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of d... Read More...

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America

With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022. VANCOUVER, BC, Aug. 26, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology ... Read More...

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. VANCOUVER, BC, July 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelic... Read More...

MINDCURE Adopts Advance Notice Policy

VANCOUVER, BC, July 12, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company wit... Read More...

Maxim Group Initiates Coverage of Mind Cure Health

VANCOUVER, BC, June 30, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health I... Read More...